Hypnomidate (Etomidate)

Etomidate enhances the activity of the GABA‑A receptor, the main inhibitory neurotransmitter system in the brain. By increasing chloride ion flow, it stabilises neuronal membranes, producing swift hypnosis and sedation with relatively modest effects on cardiovascular function.

The specific dose of Hypnomidate is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Dosing recommendations are provided in the product’s prescribing information and should be followed by qualified healthcare professionals.

Safety data for Etomidate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Hypnomidate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Compared with agents such as propofol, Etomidate (Hypnomidate) offers more stable haemodynamic profiles, making it useful in patients with limited cardiac reserve. However, it is associated with adrenal suppression, whereas propofol does not have this effect. Choice of agent depends on patient factors and procedural requirements.

Hypnomidate should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discoloured or contains particles.

Hypnomidate is administered as an intravenous injection. The solution is drawn into a sterile syringe and given as a rapid bolus for induction of anesthesia, or as a continuous infusion for maintenance of sedation, according to the clinician’s protocol.

The most serious adverse events include adrenal suppression, which can impair stress hormone production, profound myocardial depression leading to hypotension, and rare but severe allergic reactions such as anaphylaxis. Continuous monitoring of cardiovascular and respiratory status is essential during use.

Hypnomidate is contraindicated in patients with known hypersensitivity to Etomidate or any formulation components, and should be avoided in individuals with severe adrenal insufficiency. Caution is also advised for patients with significant hepatic disease or unstable cardiovascular conditions.